Adaptimmune Therapeutics (NASDAQ:ADAP) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03), Fidelity Earnings reports. The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $7.00 million.
Shares of ADAP stock traded down $0.02 during trading on Friday, reaching $0.88. The company’s stock had a trading volume of 266,200 shares, compared to its average volume of 304,870. The stock’s 50-day moving average price is $1.16 and its 200 day moving average price is $2.63. Adaptimmune Therapeutics has a 1-year low of $0.83 and a 1-year high of $6.77. The company has a market capitalization of $115.16 million, a price-to-earnings ratio of -0.92 and a beta of 1.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 6.19 and a quick ratio of 6.19.
A number of research firms have recently issued reports on ADAP. BidaskClub downgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, July 26th. ValuEngine cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 17th. Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Cowen restated a “buy” rating on shares of Adaptimmune Therapeutics in a report on Thursday. Finally, Guggenheim cut shares of Adaptimmune Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $6.59.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.